{
    "clinical_study": {
        "@rank": "56897", 
        "arm_group": [
            {
                "arm_group_label": "vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks"
            }, 
            {
                "arm_group_label": "calcipotriene", 
                "arm_group_type": "Active Comparator", 
                "description": "clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks x"
            }, 
            {
                "arm_group_label": "calcipotriene + clobetasol propionate", 
                "arm_group_type": "Active Comparator", 
                "description": "clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays for 8 weeks +  clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study  is to investigate if combined use of OLUX-E\u2122 Foam and SORILUX Foam\n      may help \"maintain\" the therapeutic benefit that is achieved with OLUX-E\u2122 Foam in the\n      treatment of moderate plaque psoriasis.\n\n      OLUX-E\u2122 is a medication that contains a corticosteroid delivered in a foam formulation.\n      SORILUX Foam is a foam formulation of calcipotriene.  Both medications have been approved by\n      the FDA for treating plaque psoriasis."
        }, 
        "brief_title": "Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "detailed_description": {
            "textblock": "This is a single-center, investigator-blind study.  Approximately 60 qualified subjects will\n      be enrolled into a 2 week treatment phase where they will receive 2 weeks of treatment with\n      Olux E foam.  After 2 weeks treatment, subjects with a PGA of 0 or 1 will be re-randomized\n      into maintenance phase.\n\n      Subjects that achieve PGA scores of >2 will be discontinued from the study and will not be\n      randomized.  Subjects that achieve PGA scores of 0 or 1 will enter an 8 week maintenance\n      phase where they will be randomized on a 1:1:1 basis to one of the following treatment\n      groups:\n\n        -  Vehicle foam (BID)\n\n        -  Sorilux foam (BID)\n\n        -  Sorilux foam (BID on weekdays) + Olux E foam (BID on weekends)\n\n      Subjects will then attend clinic visits at week 6.  At week 10 study treatment will be\n      stopped.\n\n      The maximum duration of the study is 10 weeks and consists of a Screening/Baseline Visit\n      (Week -0), Re-randomization to maintenance phase visit (Week 2), treatment follow-up visits\n      at Weeks 6, and end of treatment visit at weeks 10."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Outpatient, male or female subjects of any race, 18 years of age or higher. -Female\n             subjects of childbearing potential must have a negative urine pregnancy test within 7\n             days prior to the first dose of study drug and practice a reliable method of\n             contraception throughout the study [Exception:  Female subjects of child bearing\n             potential who are not sexually active are not required to practice a reliable method\n             of contraception and may be enrolled at the Investigator's discretion provided they\n             are counseled to remain sexually inactive for the duration of the study and\n             understand the risks involved in getting pregnant during the study.]\n\n          -  Moderate plaque type psoriasis eligible for topical therapies.\n\n          -  A Bod Surface Area (BSA) of 3-10%.\n\n          -  Physician Global Assessment(PGA) score of 3.\n\n          -  Able to understand study requirements and sign Informed Consent/Health Insurance\n             Portability and Accountability Act forms.\n\n        Exclusion Criteria:\n\n          -  Female subjects who are pregnant, breast-feeding, or who are of childbearing\n             potential and not practicing a reliable method of birth control, or male subjects\n             planning a pregnancy with their spouse or partner while in the study.\n\n          -  History of hypocalcaemia or vitamin D toxicity.\n\n          -  Serious skin condition (other than psoriasis) or uncontrolled medical condition (in\n             the opinion of the investigator).\n\n          -  Topical steroids, topical immunomodulators, topical vitamin D derivatives, tar,\n             salicylic acid, anthralin or any other topical treatment for psoriasis within 2 weeks\n             of baseline.\n\n          -  Use of any biologics within 3 months of baseline.\n\n          -  Use of other systemic psoriasis treatments (ie, oral retinoids, methotrexate,\n             cyclosporine, or other immunomodulators) within 4 weeks of baseline.\n\n          -  Use of Ultraviolet B light (UVB) or oral psoralen with ultraviolet A (PUVA) within 2\n             weeks of baseline.\n\n          -  Skin conditions (e.g. eczema) psoriasis that may interfere with evaluations of\n             psoriasis.\n\n          -  Known hypersensitivity to Sorilux Foam Ointment or any of its components.\n\n          -  Known hypersensitivity to Olux E Foam or any of its components.\n\n          -  Contraindications according to the Sorilux Foam or Olux E Foam package inserts.\n\n          -  Current drug or alcohol abuse (Investigator opinion).\n\n          -  Subject unable to commit to all the assessments required by the protocol.\n\n          -  Current enrollment in another clinical study and treatment with another experimental\n             drug or approved therapy for experimental use within 30 days prior to the Screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745133", 
            "org_study_id": "OLX0112"
        }, 
        "intervention": [
            {
                "arm_group_label": "vehicle", 
                "description": "clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks", 
                "intervention_name": "vehicle foam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "calcipotriene", 
                "description": "clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks", 
                "intervention_name": "calcipotriene", 
                "intervention_type": "Drug", 
                "other_name": "Sorilux foam 0.005% foam"
            }, 
            {
                "arm_group_label": "calcipotriene + clobetasol propionate", 
                "description": "clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks", 
                "intervention_name": "calcipotriene + clobetasol propionate", 
                "intervention_type": "Drug", 
                "other_name": "Sorilux foam + Olux E foam"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clobetasol", 
                "Calcipotriene", 
                "Calcitriol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Olux E foam", 
            "Sorilux foam"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Louisville", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40217"
                }, 
                "name": "DermResearch, PLLC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis", 
        "overall_official": {
            "affiliation": "DermResearch, PLLC", 
            "last_name": "Leon H Kircik, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "including measuring plaque elevation , scaling, erythema , body surface area involved", 
            "measure": "Physicians Global Assessment", 
            "safety_issue": "No", 
            "time_frame": "10 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745133"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Derm Research, PLLC", 
            "investigator_full_name": "Leon Kircik, M.D.", 
            "investigator_title": "Medical Doctor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Derm Research, PLLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Stiefel, a GSK Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Leon Kircik, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}